Get started

VRTX

VRTX Beginning!Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish inclination Fundamentals: Core product in strong growth, In January 26, 2021, VRTX announced that it received FDA approval for the use of Trikafta with children ages 6-11 with CF and certain mutations. In January 28, 2021, VRTX announced that it received FDA clearance for its type-1 diabetes investigational medicine and will enter the phase ½ clinical trial. Powerful toppling and bottom line growth, Net income has grown 229% from 2019 to September 2020. Currently seeking acquisition opportunities Let's wait and see
NASDAQ:VRTXLong
by jerryz73001
2
VRTX Gap Fill Play - Bullish- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. - Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts - Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact. - Price entering the gap from that day's drop. - Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued. - Bull flagging right under the gap. Key Level: $232.41 Price Target: 269.93 ATR: $6.60 Play: Bullish Gap Fill Buy the Dip under the key level to scale in Use $232.41 as inflection point. Look for breakout with increased volume Price Target: 270 Under $224 will invalidate
NASDAQ:VRTXLong
by Pr0diJ
VRTX - DAILY CHART Hi, today we are going to talk about Vertex Pharmaceuticals and its current landscape. Vertex Pharmaceuticals is poised to receive increasing attention from the market as relevant events are taking place after Proteostasis Therapeutics had unveiled "positive" data from a phase 2 clinical trial testing its triple-drug combination in patients with cystic fibrosis, however, the results were below than Vertex Pharmaceuticals similar product named Trikafta, giving Vertex an edge on the market, and possibly implying that the company could thrive over Proteostasis Therapeutics underperforming. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NASDAQ:VRTX
by Igor-Silva
VRTX Swing ShortUsing a tight stop here with a wide target due to extended nature of this last impulse up and the fact that we're almost perfectly at the 1.618 extension of the last swing high -> swing low. You can tighten your stop to directly above the highest wick of this impulse as well if you want to increase the Reward:Risk Ratio. The other thing to watch is the Fibonacci node about 2.5% below this entry (around $215). This area is possible support and could snare price action in this small range for a while. If you're shorting the asset then you're fine but if you're buying puts you may want to cover when/if we reach that area. This is not financial advice and as always, do your own research. Happy Trading, BBT For $5 a month you can get access to my personal strategy, scanner, and private trade set-ups for traditional markets and crypto. Feel free to DM me for details.
NASDAQ:VRTXShort
by BrownBearTrades
$VRTX Overbought - Shooting Star Confirmed$VRTX Overbought - beginning to retrace today closing well below yesterday's low, confirming bearish shooting star reversal candle from yesterday. Will be looking for additional 8-10% downside from today's close to the area of the 200d ema near term. (More downside possible depending on outcome of Feb ER) Target: $170-$175 range by mid February Also of note, in fundamental news...Vertex just announced today they have terminated their COO/interim CFO as "the result of personal behavior that violated Vertex's Code of Conduct and values" - possibly more fuel to power this latest downward move. Expect a gap down at the open tomorrow morning. Note: Informational analysis, not investment advice.
NASDAQ:VRTXShort
by Triple_Barrel_Capital
VRTX setting for move lowerAfter stock bounced from resistance that is intact since May 2013 and broke down upper level support @ $76 with strong follow through to November lows. Now, it is flagging near lows in front of support. With weak Biotechnology sector and market sitting on resistance it could be start of another down leg. Enter short @ $63.80 Stop above 21 MA @ $66.83 Target $58.07-$59.76 and then I expect potential break down and continuation move to low $50ish area.
NASDAQ:VRTXShort
by andrew.berg